Y-MABS THERAPEUTICS INC's ticker is YMAB and the CUSIP is 984241109. A total of 94 filers reported holding Y-MABS THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.01 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $123,770 | -62.8% | 22,710 | -53.7% | 0.00% | – |
| Q2 2023 | $332,839 | +36.0% | 49,019 | +0.4% | 0.00% | – |
| Q1 2023 | $244,654 | +9.9% | 48,833 | +7.0% | 0.00% | – |
| Q4 2022 | $222,694 | -84.0% | 45,634 | -52.6% | 0.00% | – |
| Q3 2022 | $1,390,000 | +12.8% | 96,368 | +18.4% | 0.00% | – |
| Q2 2022 | $1,232,000 | +57.7% | 81,426 | +23.9% | 0.00% | – |
| Q1 2022 | $781,000 | -20.5% | 65,717 | +8.5% | 0.00% | – |
| Q4 2021 | $982,000 | -11.3% | 60,560 | +56.2% | 0.00% | – |
| Q3 2021 | $1,107,000 | +105.4% | 38,779 | +143.2% | 0.00% | – |
| Q2 2021 | $539,000 | -49.5% | 15,947 | -54.9% | 0.00% | – |
| Q1 2021 | $1,068,000 | +58.5% | 35,326 | +159.2% | 0.00% | – |
| Q4 2020 | $674,000 | +230.4% | 13,630 | +156.5% | 0.00% | – |
| Q3 2020 | $204,000 | -12.1% | 5,314 | -1.2% | 0.00% | – |
| Q2 2020 | $232,000 | -29.7% | 5,377 | -57.4% | 0.00% | – |
| Q1 2020 | $330,000 | +41.0% | 12,630 | +40.7% | 0.00% | – |
| Q3 2019 | $234,000 | – | 8,974 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | 191,176 | $2,271,000 | 2.63% |
| Sofinnova Investments, Inc. | 2,194,278 | $26,068,000 | 1.98% |
| MPM BioImpact LLC | 443,702 | $5,271,000 | 1.42% |
| Soleus Capital Management, L.P. | 238,982 | $2,839,000 | 0.37% |
| Lombard Odier Asset Management (Switzerland) SA | 221,774 | $2,635,000 | 0.21% |
| Artal Group S.A. | 400,000 | $4,752,000 | 0.20% |
| Polar Capital Holdings Plc | 2,877,671 | $34,187,000 | 0.15% |
| ASHFORD CAPITAL MANAGEMENT INC | 106,770 | $1,268,000 | 0.14% |
| Cormorant Asset Management, LP | 150,000 | $1,782,000 | 0.14% |
| Virtus ETF Advisers LLC | 23,646 | $281,000 | 0.13% |